<DOC>
	<DOCNO>NCT00390208</DOCNO>
	<brief_summary>The purpose study compare triple therapy use Photodynamic therapy , intravitreal Dexamethasone intravitreal Ranibizumab injection versus monotherapy intravitreal Ranibizumab alone treatment Age-Related Macular Degeneration .</brief_summary>
	<brief_title>Triple Therapy - PDT Plus IVD Intravitreal Ranibizumab Versus Lucentis Monotherapy Treat Age-Related Macular Degeneration</brief_title>
	<detailed_description>This twelve month Phase II prospective mask study compare Group 1 triple therapy : Same day combination therapy PDT , 500 microgram dose ( 0.05cc ) intravitreal dexamethasone injection ( 10mg/ml vial ) , single 0.5 mg intravitreal Ranibizumab injection . This compare Group 2 monotherapy : one intravitreal injection 0.5 mg Lucentis give every four week set dose schedule . Sixty consecutive patient enrol clinical trial utilize current standard care guideline use Bay Area Retina Associates . Angiography , fundus photography perform initial visit quarterly follow-up visit . Only OCT test perform follow-up visit . Both group re-evaluated safety 12 24 month . Group 1 Following initial treatment , future re-treatments Lucentis determine PRN basis . The decision base clinical examination image evidence lesion activity . Any evidence subretinal fluid cystoid edema OCT clinical examination , evidence leakage angiogram result re-treatment . If three consecutive Ranibizumab injection Group 1 , evidence lesion recurrence growth neovascular membrane associate visual decline persistent subretinal fluid , patient treat repeat PDT/IVD/Lucentis The decision retreat Group 1 ranibizumab monthly follow-up visit dependent clinical exam , OCT measurement angiographic finding document . Group 2 Subjects receive one intravitreal injection 0.5 mg Lucentis every four week week 48 indicated FDA approval label .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Best Corrected Visual Acuity use ETDRS Charts 20/32 20/400 ( Snellen Equivalent ) study eye evidence neovascular ARMD . ( Only one eye eligible study . If eye eligible , one good visual acuity select treatment unless , base medical reason , investigator deems eye appropriate treatment study . ) All lesion subtypes enrol follow criterion Predominantly classic : Classic lesion great 50 % total lesion area Lesion must less 12 disc area Minimally classic occult : CNVM must great equal 50 % total lesion size . There must evidence recent disease progression ( heme , vision loss , recent lesion growth FA ) Lesion size must less 12 disc area . Occult : Lesions must show recent activity progression respect vision , subretinal hemorrhage subretinal fluid Less 12 disc area total size Signed informed consent Age great equal 50 year Pigment epithelial detachment great 50 % total lesion size Previous treatment ARMD study eye Previous intravitreal drug delivery study eye History vitrectomy study eye Fibrosis atrophy involve center fovea study eye Neovascular membrane concurrent retinal disease high myopia ( SER &gt; 8D ) , histoplasmosis ocular inflammatory disease . Known history glaucoma one topical medication History glaucoma filter surgery study eye History corneal transplant study eye Patients coexist macular disease diabetic macular edema Active intraocular inflammation study eye History allergy fluorescein amenable treatment Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Degenerative change macula lutea retina .</keyword>
	<keyword>Maculopathy , Age-Related</keyword>
	<keyword>Age-Related Maculopathies</keyword>
	<keyword>Age-Related Maculopathy</keyword>
	<keyword>Maculopathies , Age-Related</keyword>
	<keyword>RETINAL DEGENERATION</keyword>
	<keyword>ARMD</keyword>
	<keyword>AMD</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Visudyne</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Intravitreal Dexamethasone</keyword>
</DOC>